We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+21.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$511M
AUM Growth
+$16.2M
Cap. Flow
+$33.5M
Cap. Flow %
6.56%
Top 10 Hldgs %
48.76%
Holding
68
New
20
Increased
11
Reduced
12
Closed
13
Avg Time Held
3.9 quarters
Top 10 Avg Time Held
3.1 quarters
Top 20 Avg Time Held
3.9 quarters

Top Buys

Rank Stock Value
1
AFIB icon
Acutus Medical Inc
AFIB
+$22.8M
2
PCVX icon
Vaxcyte
PCVX
+$12.5M
3
TARA icon
Protara Therapeutics
TARA
+$8.12M
4
CRDF icon
Cardiff Oncology
CRDF
+$7.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.73M

Top Sells

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$10.6M
2
QURE icon
uniQure
QURE
+$8.55M
3
APTO
Aptose Biosciences, Inc.
APTO
+$7.38M
4
MTEM icon
Molecular Templates, Inc.
MTEM
+$6.83M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OCUL icon
1
Ocular Therapeutix
OCUL
$1.59B
$45.5M 8.91%
5,984,200
– –
2019 Q1
6 quarters
TARA icon
2
Protara Therapeutics
TARA
$155M
$43.1M 8.42%
2,558,472
+350,000
+16% +$8.12M
2019 Q3
4 quarters
ETON icon
3
Eton Pharmaceutcials
ETON
$1.52B
$28.8M 5.62%
3,640,000
– –
2018 Q4
7 quarters
CRDF icon
4
Cardiff Oncology
CRDF
$78.6M
$24.6M 4.81%
1,731,600
+1,141,600
+193% +$7.54M
2020 Q2
1 quarter
AFIB icon
5
DELISTED
Acutus Medical Inc
AFIB
$22.4M 4.37%
+749,990
New +$22.8M
2020 Q3
0 quarters
CCXI icon
6
DELISTED
ChemoCentryx, Inc.
CCXI
$19.5M 3.82%
356,000
-5,600
-2% -$301K
2019 Q3
4 quarters
NGNE icon
7
Neurogene
NGNE
$431M
$16.6M 3.25%
69,315
-685
-1% -$166K
2019 Q3
4 quarters
HROW icon
8
Harrow
HROW
$1.06B
$16.5M 3.24%
2,959,000
+249,000
+9% +$1.49M
2018 Q3
8 quarters
CDXS icon
9
Codexis
CDXS
$145M
$16.4M 3.21%
1,400,000
– –
2014 Q1
26 quarters
EIDX
10
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$15.9M 3.12%
315,550
– –
2018 Q4
7 quarters
PCVX icon
11
Vaxcyte
PCVX
$10.4B
$15.5M 3.02%
+313,000
New +$12.5M
2020 Q3
0 quarters
CLDX icon
12
Celldex Therapeutics
CLDX
$2.22B
$14.7M 2.88%
992,000
-79,000
-7% -$925K
2020 Q2
1 quarter
MGNX icon
13
MacroGenics
MGNX
$218M
$13.3M 2.6%
527,000
+26,000
+5% +$710K
2019 Q4
3 quarters
DCPH icon
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.4M 2.23%
222,000
– –
2018 Q1
10 quarters
STXS icon
15
Stereotaxis
STXS
$106M
$10.8M 2.12%
3,021,436
-490,064
-14% -$1.89M
2019 Q3
4 quarters
APTO
16
DELISTED
Aptose Biosciences, Inc.
APTO
$10.8M 2.11%
3,998
-2,958
-43% -$7.38M
2019 Q3
4 quarters
ATXI icon
17
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$10.7M 2.09%
875
-45
-5% -$547K
2018 Q4
7 quarters
TGTX icon
18
TG Therapeutics
TGTX
$8.32B
$10.4M 2.04%
390,000
-66,600
-15% -$1.53M
2018 Q1
10 quarters
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$10.4M 2.04%
+100,672
New +$5.39M
2020 Q3
0 quarters
FBIO icon
20
Fortress Biotech
FBIO
$65M
$10.3M 2.01%
255,333
– –
2020 Q2
1 quarter
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
$9.59M 1.88%
682,500
– –
2020 Q1
2 quarters
CMRX icon
22
DELISTED
Chimerix, Inc.
CMRX
$9.56M 1.87%
3,841,500
+1,736,500
+82% +$5.13M
2020 Q2
1 quarter
MCRB icon
23
Seres Therapeutics
MCRB
$25.4M
$9.49M 1.86%
+16,766
New +$5.58M
2020 Q3
0 quarters
SIOX
24
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$9.42M 1.84%
+2,039,100
New +$6.73M
2020 Q3
0 quarters
KNSA icon
25
Kiniksa Pharmaceuticals
KNSA
$6.13B
$8.78M 1.72%
338,000
-6,500
-2% -$122K
2020 Q2
1 quarter
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2020 Portfolio in Review

As of Q3 2020, Opaleye Management held 68 positions worth $511M, up 3.3% from $495M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management deployed $33.5M of net new capital in Q3 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was Acutus Medical Inc: 749,990 shares worth $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $7.38M trimmed.

  • Opaleye Management's largest Q3 2020 buy was Acutus Medical Inc: 749,990 shares worth $22.4M.
  • Opaleye Management added most to Protara Therapeutics in Q3 2020, an estimated $8.12M increase.
  • Opaleye Management's biggest Q3 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $7.38M.
  • Opaleye Management fully exited Odonate Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $10.6M.
  • Opaleye Management's ten largest holdings make up 49% of its $511M portfolio in Q3 2020.
  • Opaleye Management opened 20 new positions and closed 13 in Q3 2020.
  • Opaleye Management's portfolio value rose 3.3% quarter-over-quarter to $511M.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.